|
Rheumatoid Arthritis
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results support a role for TRAF6 in the pathogenesis of RA, and suggest that the TRAF6 blockade may be a potential strategy in the management of RA.
|
25522907 |
2015 |
|
Rheumatoid Arthritis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Hence, the first-in-class TRAF6-Ubc13 inhibitor C25-140 expands the toolbox for studying the impact of the ubiquitin system on immune signaling and underscores the importance of TRAF6 E3 ligase activity in psoriasis and rheumatoid arthritis.
|
29950522 |
2018 |
|
Rheumatoid Arthritis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of NOD2 gene expression significantly decreased NF-κB, TRAF6, and IKK levels, but not caspase-1 levels, in RA FLS.
|
28240593 |
2017 |
|
Rheumatoid Arthritis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, we investigated whether genetic variants in OPG, RANK, RANKL and TRAF6 are associated with the rate of joint destruction in RA.
|
24886600 |
2014 |
|
Rheumatoid Arthritis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We evaluated whether a single-nucleotide polymorphism (SNP) of the TRAF6 gene previously associated with systemic lupus erythematosus and rheumatoid arthritis may be a common risk factor for systemic sclerosis (SSc) and giant cell arteritis (GCA).
|
22589256 |
2012 |
|
Rheumatoid Arthritis
|
0.500 |
Biomarker
|
disease |
BEFREE |
TRAF6 in RA-FLSs was inhibited using Lentiviral-TRAF6-shRNA transfection.
|
28506571 |
2017 |
|
Rheumatoid Arthritis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study for the first time ever demonstrated an association between a genetic variant of TRAF6 and low BMD among patients with RA.
|
30506403 |
2019 |
|
Rheumatoid Arthritis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
SIN effectively inhibited MyD88 and TRAF-6 expression in RA-FLS, which may be one of the important molecular mechanisms involved in RA treatment and prevention of cartilage and subchondral bone destruction.
|
26782542 |
2015 |
|
Rheumatoid Arthritis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data indicate the presence of association of TRAF6 with SLE, consistent with the previous report of association with RA.
|
22231568 |
2012 |
|
Rheumatoid Arthritis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In addition, two targets of miR-146a, namely tumor necrosis factor receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK-1), were similarly expressed between rheumatoid arthritis patients and control individuals, despite increased expression of miR-146a in patients with rheumatoid arthritis.
|
18759964 |
2008 |
|
Rheumatoid Arthritis
|
0.500 |
Biomarker
|
disease |
BEFREE |
As a result, five shared risk feature genes, CD80, EGFR, FN1, GSK3B and TRAF6 were found and proven to be associated with rheumatoid arthritis by previous reports.
|
21910999 |
2011 |
|
Coronary Artery Disease
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Significantly lower levels of IRAK-1 (0.38 ± 0.02; p = 0.0072) and TRAF-6 (0.44 ± 0.02; p = 0.0146) was found in CAD patients with the CC genotype.
|
23794009 |
2014 |
|
Coronary Artery Disease
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Levels of miR-146a/b, IRAK1 mRNA, TRAF6 mRNA and TLR4 mRNA/TLR4 protein were significantly higher in the CAD group than in the non-CAD group (all P<0.01).
|
20524934 |
2010 |
|
Coronary Arteriosclerosis
|
0.310 |
Biomarker
|
disease |
BEFREE |
miR-146a polymorphism influences levels of miR-146a, IRAK-1, and TRAF-6 in young patients with coronary artery disease.
|
23794009 |
2014 |
|
Christ-Siemens-Touraine syndrome
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
A rare heterozygous TRAF6 variant is associated with hypohidrotic ectodermal dysplasia.
|
22296312 |
2012 |
|
Christ-Siemens-Touraine syndrome
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
Functional studies for the TRAF6 mutation associated with hypohidrotic ectodermal dysplasia.
|
22924441 |
2013 |
|
Christ-Siemens-Touraine syndrome
|
0.250 |
Biomarker
|
disease |
BEFREE |
These results support the involvement of the TAB2/TRAF6/TAK1 signalling complex in the Edar signal transduction pathway and have important implications for our understanding of NF-kappaB activation and EDs in human.
|
16251197 |
2005 |
|
Christ-Siemens-Touraine syndrome
|
0.250 |
Biomarker
|
disease |
BEFREE |
Traf6 is known to function as an intracellular adaptor protein for Troy and examination of Traf6 mutant mice revealed abnormalities in molar teeth that are similar but more severe than those produced by mutations in Eda signalling molecules.
|
14699584 |
2004 |
|
Christ-Siemens-Touraine syndrome
|
0.250 |
Biomarker
|
disease |
BEFREE |
TRAF6 does not associate with the cytoplasmic tail of the dl protein (DL)/ectodysplasin receptor (EDAR) receptor, which, when mutated, results in hypohidrotic (anhidrotic) ectodermal dysplasia.
|
12060722 |
2002 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a zinc-finger-containing protein, we focused on TRAF6, which is related to cancer and inflammation.
|
28884970 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although TRAF6 has been shown to have oncogenic activity in various malignant tumors, the details remain unclear.
|
29463844 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TRAF6 has been implicated in the invasive growth and metastasis of various types of cancer, including squamous cell carcinoma, gastric cancer, myelodysplastic syndromes and acute myeloid leukemia.
|
28789366 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Network-based meta-analysis identified FN1 and TRAF6 to be the most highly ranked hub genes among the overexpressed and underexpressed genes, respectively, both of which are involved in pathways in cancer.
|
29625265 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also demonstrated that TRAF6 is closely associated with EMT process and cancer stem cells using a Tgfbr1/Pten 2cKO mice SCCHN model and human SCCHN tissue microarray.
|
29193723 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro and in vivo cancer cell apoptosis triggered by competitive binding of Cinchona alkaloids to the RING domain of TRAF6.
|
31074699 |
2019 |